Regeneron Pharmaceuticals, Inc. · NASDAQ:REGN

Regeneron Pharmaceuticals — Technical Presentation (February 2026)

19 slides from Regeneron Pharmaceuticals's technical presentation, Feb 7, 2026

  1. Slide 1: Safety and Efficacy of Aflibercept 8 mg in Patients with nAMD or DME: Primary Results from ELARA

    Safety and Efficacy of Aflibercept 8 mg in Patients with nAMD or DME: Primary Results from the Phase 3b ELARA Trial David M. Brown, MD,1 on behalf of the ELARA study investigators 1Retina Consultants of Texas, Retina Consultants of America, Houston, TX, USA Presented at Angiogenesis, Exudation, and

  2. Slide 2: Disclosures

    Disclosures • David Brown has served as scientific advisor for Regeneron/Bayer and Genentech/Roche and as a member of the Regeneron Combination Products Steering Committee • The ELARA trial was sponsored by Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, USA). The sponsor participated in the design

  3. Slide 3: Background

    Background • Aflibercept 8 mg at extended dosing intervals demonstrated BCVA gains and CRT reductions comparable to aflibercept 2q8 over 2 years in pivotal trials in nAMD (PULSAR) and DME (PHOTON)1-4 – In both trials, the majority of aflibercept 8 mg-treated patients achieved ≥16-week dosing interva

  4. Slide 4: ELARA Study Design

    ELARA Study Design 1110 patients enrolled across 53 US sites Study eyes (N=1110) previously treated with ≥3 anti-VEGF injections within T&E regimen per DRM criteriaa,b 5 months prior to study start in: nAMD (n=622) DME (n=488) 0 4 8 12 16 20 24 96 Patients aged Patients aged EOS ≥50 years with CNV ≥

  5. Slide 5: Patient Disposition at Week 24

    Patient Disposition at Week 24 nAMD DME Total Enrolled 622 488 1110 Completed Week 24, n (%) 595 (95.7) 471 (96.5) 1066 (96.0) Reason for discontinuation, n Withdrawal of consent 20 10 30 Adverse event 4 3 7 Death 2 2 4 Lost to follow-up 1 2 3 SAF. SAF, safety analysis set. 6

  6. Slide 6: Baseline Demographics

    Baseline Demographics nAMD DME Total (n=622) (n=488) (N=1110) Age, mean (SD), years 77.1 (8.5) 62.8 (9.8) 70.8 (11.5) Female, n (%) 360 (57.9) 203 (41.6) 563 (50.7) Hispanic or Latino, n (%) 43 (6.9) 114 (23.4) 157 (14.1) Race, n (%) White 589 (94.7) 387 (79.3) 976 (87.9) Black or African American 8

  7. Slide 7: Baseline Characteristics of Study Eye

    Baseline Characteristics of Study Eye nAMD DME Total (n=622) (n=488) (N=1110) BCVA, mean (SD), 68.0 (15.3) 69.8 (13.4) 68.8 (14.5) ETDRS letters Snellen equivalent 20/40 20/40 20/40 Patients with BCVA >73 276 (44.4) 232 (47.5) 508 (45.8) ETDRS letters, n (%) CST, mean (SD), µm 254.3 (66.0) 328.1 (10

  8. Slide 8: Previous Anti-VEGF Treatment Within Prior 6 Months

    Previous Anti-VEGF Treatment Within Prior 6 Months Proportion of patients, % Only nAMD DMEa Total (n=622) (n=488) (N=1110) SAF. aData for 1 patient in the DME cohort were missing. bRanibizumab or ranibizumab biosimilar (ranibizumab-eqrn or ranibizumab-nuna). 9

  9. Slide 9: Number of Previous Anti-VEGF Injections in Study Eye

    Number of Previous Anti-VEGF Injections in Study Eye 6 Months Prior to Study Start nAMD DMEa Total (n=622) (n=488) (N=1110) Previous anti-VEGF injections in the study eye in prior 6 months, n (%) 3 injections 181 (29.1) 195 (40.0) 376 (33.9) 4 injections 212 (34.1) 175 (35.9) 387 (34.9) 5 injections

  10. Slide 10: Mean Change in BCVA in Patients with nAMD

    Mean Change in BCVA Through Week 24 in Patients with nAMD Mean change in BCVA, ETDRS letters +2.5 letters Week Proportion of Mean number Mean BCVA Mean change in patients with of injections at BL BCVA at Week 24 ≥5-letter gain through Week 24 at Week 24 nAMD (n=622) 68.0 letters +2.5 letters 32.9% 6

  11. Slide 11: Mean Change in CST in Patients with nAMD

    Mean Change in CST Through Week 24 in Patients with nAMD Week Mean change -27.1 µm in CST, µm Mean number Mean CST Mean change in of injections at BL CST at Week 24 through Week 24 nAMD (n=622) 254.3 µm -27.1 µm 6.0 SAF, observed cases.

  12. Slide 12: Mean Change in BCVA in Patients with DME

    Mean Change in BCVA Through Week 24 in Patients with DME Mean change in BCVA, ETDRS letters +3.2 letters Week Proportion of Mean number Mean BCVA Mean change in patients with of injections at BL BCVA at Week 24 ≥5-letter gain through Week 24 at Week 24 DME (n=488) 69.8 letters +3.2 letters 36.8% 5.8

  13. Slide 13: Mean Change in CST in Patients with DME

    Mean Change in CST Through Week 24 in Patients with DME Week Mean change in CST, µm -39.7 µm Mean number Mean CST Mean change in of injections at BL CST at Week 24 through Week 24 DME (n=488) 328.1 µm -39.7 µm 5.8 SAF, observed cases.

  14. Slide 14: Ocular Safety in the Study Eye Through Week 24

    Ocular Safety in the Study Eye Through Week 24 nAMD DME Total (n=622) (n=488) (N=1110) Patients with ≥1 ocular TEAE, n (%) 106 (17.0) 109 (22.3) 215 (19.4) Ocular TEAEs occurring in >15 patients overall, n (%) Conjunctival hemorrhage 21 (3.4) 18 (3.7) 39 (3.5) Cataract 7 (1.1) 13 (2.7) 20 (1.8) Vitr

  15. Slide 15: Intraocular Inflammation in the Study Eye Through Week 24

    Intraocular Inflammation in the Study Eye Through Week 24 nAMD DME Total (n=622) (n=488) (N=1110) Patients with ≥1 IOI TEAE, n (%) 6 (1.0) 5 (1.0) 11 (1.0) Endophthalmitis 1 (0.2) 3 (0.6) 4 (0.4) Eye inflammation 2 (0.3) 0 2 (0.2) Iritis 1 (0.2) 1 (0.2) 2 (0.2) Eye infection 1 (0.2) 0 1 (<0.1) Irido

  16. Slide 16: Intraocular Pressure in the Study Eye Through Week 24

    Intraocular Pressure in the Study Eye Through Week 24 nAMD DME Total (n=622) (n=488) (N=1110) Patients with ≥10 mmHg increase 16/616 (2.6%) 15/486 (3.1%) 31/1102 (2.8%) in pre-dose IOP from baselinea Patients with pre-dose IOP 10/622 (1.6%) 13/488 (2.7%) 23/1110 (2.1%) ≥25 mmHga Patients with pre- o

  17. Slide 17: Mean Change in Pre-dose IOP in All Patients

    Mean Change in Pre-dose IOP in IOP, mmHg in All Patients Through Week 24 Mean change -0.2 mmHg Week SAF.

  18. Slide 18: Non-ocular Safety Through Week 24

    Non-ocular Safety Through Week 24 nAMD DME Total (n=622) (n=488) (N=1110) Patients with ≥1 serious non-ocular 31 (5.0) 35 (7.2) 66 (5.9) TEAE, n (%) Serious non-ocular TEAEs occurring in ≥3 patients overall, n (%) Cerebrovascular accident 1 (0.2) 3 (0.6) 4 (0.4) Myocardial infarction 2 (0.3) 2 (0.4)

  19. Slide 19: ELARA Summary of Week 24 Results

    ELARA Summary of Week 24 Results • Aflibercept 8 mg every 4 weeks achieved meaningful functional and anatomic improvements at Week 24 in patients previously treated with anti-VEGF agents for nAMD or DME • The safety profile of monthly dosing with aflibercept 8 mg through Week 24 was consistent with

Regeneron Pharmaceuticals — Technical Presentation (February 2026) on 6ix